GermanyGermany

Gene synthesis companies establish measures to counter bioterrorism

20.11.2009

Regensburg – The five largest suppliers of synthetic DNA will establish common measures to prevent misuse of synthetically produced DNA by bioterorrists or criminals (see more). Yesterday, Blue Heron Biotechnology, DNA2.0, GENEART, GenScript and Integrated DNA Technologies, which together represent an 80% share of the synthetic DNA market, announced the establishment of a common screening protocol that will be applied to every single synthetic gene order. "We are proud to announce the formation of the International Gene Synthesis Consortium", said John Mulligan, CSO of Blue Heron Biotechnology.
The IGSC's "Harmonized Screening Protocol" is comprised of the screening of gene sequences against a regulated pathogen database developed by the consortium and one or more of the internationally coordinated sequence reference databanks, such as NCBI/GenBank, EBI/EMBL, or DDBJ. Amino acid sequences of possible translation products for each ordered synthetic gene will also be screened. Purchasers of synthetic genes will also be screened in accordance with national guidelines. Furthermore, the IGSC companies have agreed to keep all screening, customer, and order records for at least eight years. IGSC companies have also reserved the right to refuse to fill any order, and to notify authorities upon identification of potentially problematic orders, and will coordinate efforts with local and national law enforcement and intelligence agencies. Finally, the five companies will comply with all applicable laws and regulations governing the synthesis, possession, transportation, export and import of gene synthesis and related products.
The development of the promising field of synthetic biology could be hampered - especially in Europe - by negative public perception, according to experts. "While 51% of all reports about Synbio in US newspapers are positive, in the EU only 28% are positive," said Dr. Elenore Pauwels from US-based Synbio Project (Washington). According to the US ethicist, most people are concerned that bioterrorists or states could misuse synthetic DNA sequences to make a novel bioweapon from scratch. The growing field provides a variety of biotech applications, such as the construction of microorganisms with specific desirable properties.

GermanyGermany

07.03.2012

The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...

GermanyGermany

07.03.2012

Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...

GermanyGermany

05.03.2012

Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...

GermanyGermany

05.03.2012

German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....

GermanyGermany

29.02.2012

Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...

GermanyGermany

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...

27.01.2012

Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...

GermanyGermany

20.01.2012

Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...

GermanyGermany

17.01.2012

Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...

GermanyGermany

10.01.2012

Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-germany/article/gene-synthesis-companies-establish-measures-to-counter-bioterrorism.html

Events

All Events

Stock list

All quotes

TOP

  • PHARMING (NL)0.48 EUR11.63%
  • MDX HEALTH (B)3.80 EUR10.79%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK8.53%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.46 EUR-10.26%

TOP

  • WILEX (D)2.82 EUR231.8%
  • ADDEX (CH)3.80 CHF58.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)70.00 SEK44.9%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.67 USD-23.8%
  • VITA 34 (D)4.18 EUR-20.4%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)431.00 GBP676.6%
  • PAION (D)2.42 EUR255.9%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.6%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.4%

No liability assumed, Date: 30.07.2014


Current issue

All issues

Product of the week

Products